Attention Deficit Hyperactivity clinical trials

Explore recruiting attention deficit hyperactivity clinical trials.

Recruiting attention deficit hyperactivity studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Attention Deficit Hyperactivity trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents aged 6 to 17 Years with Attention-deficit/Hyperactivity Disorder

Sweden, Netherlands, Spain, Belgium, Germany

Therapeutic use (Phase IV) EU CTIS Study details

Microdosing with a serotonergic agent for ADHD and emotion regulation: biological factors explaining and predicting treatment response

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

EEG-MRI Study of the Effect of Methylphenidate on Neural Mechanisms in Adult Patients With ADHD With or Without Mood Disorders: a Randomized Controlled Trial Versus Placebo

France

Phase II and Phase III (Integrated) EU CTIS Study details

LAMAinDiab - lisdexamphetamine vs methylphenidate for pediatric patients with ADHD and type 1 diabetes - a randomized crossover clinical trial.

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to test how BI 3031185 is tolerated by people with borderline personality disorder or attention-deficit/hyperactivity disorder.

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

Randomized, placebo-controlled clinical trial to investigate the safety and efficacy of two dexamfetamine sulfate formulations in adults with ADHD and moderate to severe depression (DEXAD)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Attention Deficit Hyperactivity trials by city

Attention Deficit Hyperactivity in Toronto Attention Deficit Hyperactivity in Vancouver Attention Deficit Hyperactivity in Montreal Attention Deficit Hyperactivity in Calgary Attention Deficit Hyperactivity in Edmonton Attention Deficit Hyperactivity in Ottawa Attention Deficit Hyperactivity in Winnipeg Attention Deficit Hyperactivity in Quebec City Attention Deficit Hyperactivity in Hamilton Attention Deficit Hyperactivity in Kitchener Attention Deficit Hyperactivity in London Attention Deficit Hyperactivity in Halifax Attention Deficit Hyperactivity in New York Attention Deficit Hyperactivity in Los Angeles Attention Deficit Hyperactivity in Chicago Attention Deficit Hyperactivity in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease